Lim kinasemodulating agents for neurofibromatoses therapy and methods for screening for same
AssigneeUniversity of Central Florida Research Foundation, Inc.
InventorCristina Fernandez-Valle
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating a patient at risk of developing or having a neurofibromatosis or a sporadic schwannoma. In exemplary embodiments, the method involves administering to a subject in need an effective amount of a LIMK modulating agent. Also disclosed are compounds newly identified to be inhibitors of Merlin-null Schwann cell proliferation and/or survival.
Claims21
1-47. (canceled)
A method for treating a neurofibromatosis in a subject, the method comprising administering to the subject an effective amount of a LIMK modulating agent, prodrugs, analogs, derivatives, metabolites, and/or pharmaceutically acceptable salts thereof.
A method of inhibiting Schwann cell proliferation in a subject comprising administering an effective amount of an LIMK modulating agent, or prodrug, analog, derivative, metabolite, and/or pharmaceutically acceptable salt thereof, to the subject to inhibit the expression or action of LIMK.
A method of screening for compounds capable of affecting a neurofibromatosis, said method comprising
- contacting at least one LIMK modulating test compound with at least one NF2-inactivated cell;
- and
- detecting for growth of or cytotoxicity to said at least one NF2-inactivated cell;
- wherein a test compound that modulates growth of or cytotoxicity to said at least one NF2-inactivated cell is identified as a potential LIMK modulating agent;
- wherein said method is set up in a high throughput format, wherein said at least one NF2-inactivated cell comprises a multiplicity of cell samples separated and disposed in individual wells in a multi-well plate.
Dependencies are inferred from the claim text.